BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2

Reuters

Mar 12

BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2

BioMarin reported new data from studies of VOXZOGO (vosoritide) in children with achondroplasia that will be presented at the 2026 ACMG Annual Clinical Genetics Meeting. In a study of children who started treatment before age 2, the least squares mean difference in upper-to-lower body segment ratio versus untreated children was −0.33 at year 1 (p=0.0005) and −0.53 at year 4 (p<0.0001). Among more than 20 children who began VOXZOGO between 0.5 to <2 years of age, average additional height gain after four years was 4.7 cm (p=0.0002) versus untreated children. BioMarin also cited real-world findings in Japan showing mean height change from baseline of 9.91 cm at 12 months and 15.62 cm at 24 months in children under age 2 receiving VOXZOGO.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603120905PR_NEWS_USPR_____SF07983) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2618132439"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618132439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618132439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618132439","market":"fut","top_or_hot":-1,"title":"BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioMarin reported new data from studies of VOXZOGO (vosoritide) in children with achondroplasia that will be presented at the 2026 ACMG Annual Clinical Genetics Meeting. In a study of children who started treatment before age 2, the least squares mean difference in upper-to-lower body segment ratio versus untreated children was −0.33 at year 1 (p=0.0005) and −0.53 at year 4 (p&lt;0.0001). Among more than 20 children who began VOXZOGO between 0.5 to &lt;2 years of age, average additional height gain after four years was 4.7 cm (p=0.0002) versus untreated children. BioMarin also cited real-world findings in Japan showing mean height change from baseline of 9.91 cm at 12 months and 15.62 cm at 24 months in children under age 2 receiving VOXZOGO.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603120905PR_NEWS_USPR_____SF07983) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioMarin reported new data from studies of VOXZOGO (vosoritide) in children with achondroplasia that will be presented at the 2026 ACMG Annual Clinical Genetics Meeting. In a study of children who started treatment before age 2, the least squares mean difference in upper-to-lower body segment ratio versus untreated children was −0.33 at year 1 (p=0.0005) and −0.53 at year 4 (p&lt;0.0001). Among more than 20 children who began VOXZOGO between 0.5 to &lt;2 years of age, average additional height gain after four years was 4.7 cm (p=0.0002) versus untreated children. BioMarin also cited real-world findings in Japan showing mean height change from baseline of 9.91 cm at 12 months and 15.62 cm at 24 months in children under age 2 receiving VOXZOGO.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603120905PR_NEWS_USPR_____SF07983) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4566","symbol_name":"资本集团","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL6VK03b:1","article_id":"2618132439","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618132439","pubTimestamp":1773320995,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2. BioMarin reported new data from studies of VOXZOGO  in children with achondroplasia that will be presented at the 2026 ACMG Annual Clinical Genetics Meeting. In a study of children who started treatment before age 2, the least squares mean difference in upper-to-lower body segment ratio versus untreated children was 0.33 at year 1  and 0.53 at year 4 . Among more than 20 children who began VOXZOGO between 0.5 to <2 years of age, average additional height gain after four years was 4.7 cm  versus untreated children. BioMarin also cited real-world findings in Japan showing mean height change from baseline of 9.91 cm at 12 months and 15.62 cm at 24 months in children under age 2 receiving VOXZOGO.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4566":"资本集团","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4139":"生物科技","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BMRN":"拜玛林制药"},"translate_title":"BioMarin报告VOXZOGO试验数据显示，2岁前接受治疗的软骨发育不全儿童在四岁时身高增加4.7 cm","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":0.9},"content_text":"BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2\n    \n\n        BioMarin reported new data from studies of VOXZOGO (vosoritide) in children with achondroplasia that will be presented at the 2026 ACMG Annual Clinical Genetics Meeting. In a study of children who started treatment before age 2, the least squares mean difference in upper-to-lower body segment ratio versus untreated children was −0.33 at year 1 (p=0.0005) and −0.53 at year 4 (p<0.0001). Among more than 20 children who began VOXZOGO between 0.5 to <2 years of age, average additional height gain after four years was 4.7 cm (p=0.0002) versus untreated children. BioMarin also cited real-world findings in Japan showing mean height change from baseline of 9.91 cm at 12 months and 15.62 cm at 24 months in children under age 2 receiving VOXZOGO.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603120905PR_NEWS_USPR_____SF07983) on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}